Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 18/20 | 0.39 |
| ▸ | PARP2 | Q9UGN5 | 5/20 | 0.39 |
| ▸ | PARP6 | Q2NL67 | 4/20 | 0.39 |
| ▸ | PARP3 | Q9Y6F1 | 4/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3880463 | 0.90 | MLYCD (0.34) | PIK3CG | |
| SCHEMBL3880495 | 0.89 | HRH3 (0.39) | PARP1PARP2PARP6PARP3PIK3CG | |
| SCHEMBL3879154 | 0.89 | PIK3CG (0.34) | PIK3CG | |
| SCHEMBL3882084 | 0.86 | HRH3 (0.47) | PARP1PARP2PARP6PARP3KCNH2 | |
| SCHEMBL3881400 | 0.85 | PIK3CG (0.32) | PIK3CG | |
| SCHEMBL3878471 | 0.83 | PIK3CG (0.30) | PIK3CG | |
| SCHEMBL3879086 | 0.81 | PIK3CG (0.32) | PIK3CG | |
| SCHEMBL3880700 | 0.80 | LCAT (0.35) | — | |
| SCHEMBL3878671 | 0.79 | CHRM4 (0.33) | — | |
| SCHEMBL3880548 | 0.79 | PIP5K1C (0.40) | PARP1PARP2PARP6PARP3USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1858900-B1 | FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR | GLAXO GROUP LTD (GB) | 2009-01-07 | — | — | EP | claimed |
| US-20080161289-A1 | Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor | GLAXO GROUP LIMITED | 2008-07-03 | — | — | US | claimed |
| EP-1858900-B1 | FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR | GLAXO GROUP LTD (GB) | 2009-01-07 | — | — | EP | disclosed |
| US-20080161289-A1 | Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor | GLAXO GROUP LIMITED | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161289-A1 | Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor | HRH3, HRH4, HRH2 | PARP1 4142/4885PARP2 4310/4885PARP6 3144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.